Breaking News Instant updates and real-time market news.

CDXS

Codexis

$17.49

0.29 (1.69%)

, NSRGY

Nestle

$0.00

(0.00%)

07:10
01/10/20
01/10
07:10
01/10/20
07:10

Codexis, Nestle Health Science sign development agreement for CDX-7108

Codexis (CDXS) and Nestle Health Science (NSRGY)have signed an agreement to advance a lead candidate discovered through a Strategic Collaboration Agreement into preclinical development and early clinical studies. The SCA, signed in 2017, was an agreement to co-discover new enzyme therapy candidates for Nestle Health Science's nutritional therapies portfolio. The companies' new agreement will advance the development of CDX-7108, the lead candidate for a potential treatment of a GI disorder. In parallel, the original SCA will be extended through the end of 2021 to support the discovery of therapeutic candidates for additional disorders.Under the Development Agreements Codexis and Nestle Health Science will retain joint ownership over the rights to CDX-7108, as they move this therapeutic enzyme candidate into preclinical and clinical development.

CDXS

Codexis

$17.49

0.29 (1.69%)

NSRGY

Nestle

$0.00

(0.00%)

  • 17

    Feb

CDXS Codexis
$17.49

0.29 (1.69%)

01/15/19
JEFF
01/15/19
NO CHANGE
Target $20
JEFF
Buy
Codexis price target raised to $20 from $15 at Jefferies
Jefferies analyst Brandon Couillard raised his price target for Codexis to $20 and keeps a Buy rating on the shares after meetings with management. The analyst's new target incorporates $4 per share of value for the company's novel biotherapeutics pipeline, for which he sees enthusiasm building over the year with two programs expected to be partner-able by the end of 2019. The value of Codexis' CodeEvolver platform as a drug discovery engine remains underappreciated, Couillard tells investors in a research note. In 2019 the analyst believes the company's "multiple legs of growth story" will come together.
01/17/19
FANA
01/17/19
UPGRADE
Target $19
FANA
Outperform
Codexis upgraded to Outperform from Neutral at First Analysis
First Analysis analyst Steven Schwartz upgraded Codexis to Outperform from Neutral following a meeting with management that he said gave him increased confidence in the company's opportunity to sustain rapid revenue growth. Schwartz, who projects 19% revenue growth for Codexis in 2019, has a $19 price target on the stock.
02/27/19
CHLM
02/27/19
NO CHANGE
Target $25
CHLM
Buy
Codexis price target raised to $25 from $20 at Craig-Hallum
Craig-Hallum analyst Matt Hewitt raised his price target for Codexis to $25 from $20 following the company's Q4 update and as it continues to make progress on multiple initiatives to drive growth going forward. The analyst reiterates a Buy rating on the shares.
03/04/19
HCWC
03/04/19
NO CHANGE
Target $22.5
HCWC
Buy
Codexis price target raised to $22.50 from $16.50 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised his price target for Codexis to $22.50 following the company's 2018 results and keeps a Buy rating on the shares. The analyst believes Codexis' food products and next-generation sequencing products could be the company's primary growth drivers in 2019 and 2020.
NSRGY Nestle
$0.00

(0.00%)

06/27/19
HSBC
06/27/19
INITIATION
HSBC
Hold
Nestle initiated with a Hold at HSBC
HSBC earlier today initiated coverage of Nestle with a Hold rating and 105 francs price target.
09/09/19
DBAB
09/09/19
DOWNGRADE
DBAB
Hold
Nestle downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Gerry Gallagher downgraded Nestle to Hold from Buy with a price target of 120 francs.
09/25/19
RBCM
09/25/19
DOWNGRADE
RBCM
Underperform
Nestle downgraded to Underperform from Sector Perform at RBC Capital
RBC Capital analyst James Jones downgraded Nestle to Underperform from Sector Perform and lowered his price target for the shares to 92 francs from 98 francs. The analyst believes the company's "easy victories have been won" and that reaching the bottom-end of its mid-single-digit revenue growth target will be a "big ask."
01/08/20
EXAN
01/08/20
DOWNGRADE
EXAN
Underperform
Nestle downgraded to Underperform from Neutral at Exane BNP Paribas
Exane BNP Paribas analyst Jeff Stent downgraded Nestle to Underperform from Neutral. The analyst cites valuation for the downgrade and believes the company will be challenged to accelerate growth this year.

TODAY'S FREE FLY STORIES

BA

Boeing

$324.11

-7.89 (-2.38%)

14:08
01/20/20
01/20
14:08
01/20/20
14:08
Periodicals
Boeing close to securing $10B loan, Bloomberg reports »

Boeing is close to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

CAE

CAE

$29.65

-0.14 (-0.47%)

14:05
01/20/20
01/20
14:05
01/20/20
14:05
Hot Stocks
CAE appoints Todd Probert as Group President, Defense & Security »

CAE announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

ACC

American Campus

$46.31

-0.085 (-0.18%)

14:03
01/20/20
01/20
14:03
01/20/20
14:03
Recommendations
American Campus analyst commentary  »

American Campus announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

UPS

UPS

$118.61

0.005 (0.00%)

14:02
01/20/20
01/20
14:02
01/20/20
14:02
Hot Stocks
UPS launches e-commerce plug-ins as part of UPS Digital Access Program »

UPS announced that it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

WINS

Wins Finance

$12.50

-1.2 (-8.76%)

13:58
01/20/20
01/20
13:58
01/20/20
13:58
Hot Stocks
Wins Finance announces submission of compliance plan to Nasdaq »

Wins Finance announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$167.06

0.82 (0.49%)

13:55
01/20/20
01/20
13:55
01/20/20
13:55
Recommendations
Microsoft price target raised to $175 from $160 at Stifel »

Stifel analyst Brad…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 25

    Feb

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

13:52
01/20/20
01/20
13:52
01/20/20
13:52
Periodicals
Softbank says WeWork still good business at core, Bloomberg reports »

SoftBank (SFTBY;SFTBF)…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Feb

EGLE

Eagle Bulk Shipping

$4.25

-0.03 (-0.70%)

13:40
01/20/20
01/20
13:40
01/20/20
13:40
Conference/Events
Eagle Bulk Shipping to host conference call »

Management discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

SMUUY

Siam Commercial Bank

$0.00

(0.00%)

13:39
01/20/20
01/20
13:39
01/20/20
13:39
Downgrade
Siam Commercial Bank rating change  »

Siam Commercial Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMUUY

Siam Commercial Bank

$0.00

(0.00%)

13:38
01/20/20
01/20
13:38
01/20/20
13:38
Downgrade
Siam Commercial Bank rating change  »

Siam Commercial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMUUY

Siam Commercial Bank

$0.00

(0.00%)

13:37
01/20/20
01/20
13:37
01/20/20
13:37
Downgrade
Siam Commercial Bank rating change  »

Siam Commercial Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMUUY

Siam Commercial Bank

$0.00

(0.00%)

13:37
01/20/20
01/20
13:37
01/20/20
13:37
Downgrade
Siam Commercial Bank rating change  »

Siam Commercial Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNVVY

ConvaTec

$0.00

(0.00%)

13:35
01/20/20
01/20
13:35
01/20/20
13:35
Downgrade
ConvaTec rating change  »

ConvaTec downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:35
01/20/20
01/20
13:35
01/20/20
13:35
General news
FX Summary: Activity was moribund »

FX Summary: Activity was…

KSU

Kansas City Southern

$166.57

4.77 (2.95%)

13:31
01/20/20
01/20
13:31
01/20/20
13:31
Recommendations
Kansas City Southern analyst commentary  »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$182.16

-0.53 (-0.29%)

13:06
01/20/20
01/20
13:06
01/20/20
13:06
Recommendations
BMO keeps 'top pick' status on Salesforce, boosts price target to $210 »

BMO Capital analyst Keith…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Mar

SNYYF

Sany Heavy

$0.00

(0.00%)

12:56
01/20/20
01/20
12:56
01/20/20
12:56
Upgrade
Sany Heavy rating change  »

Sany Heavy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATDRY

Auto Trader Group

$0.00

(0.00%)

12:52
01/20/20
01/20
12:52
01/20/20
12:52
Upgrade
Auto Trader Group rating change at Goldman Sachs »

Auto Trader Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIOSF

Atresmedia

$0.00

(0.00%)

12:50
01/20/20
01/20
12:50
01/20/20
12:50
Downgrade
Atresmedia rating change at Goldman Sachs »

Atresmedia downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGDDF

Lagardere

$0.00

(0.00%)

12:48
01/20/20
01/20
12:48
01/20/20
12:48
Downgrade
Lagardere rating change at Goldman Sachs »

Lagardere downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WPP

WPP

$66.38

-0.34 (-0.51%)

12:47
01/20/20
01/20
12:47
01/20/20
12:47
Downgrade
WPP rating change at Goldman Sachs »

WPP downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTKWY

Wolters Kluwer

$0.00

(0.00%)

12:46
01/20/20
01/20
12:46
01/20/20
12:46
Downgrade
Wolters Kluwer rating change at Goldman Sachs »

Wolters Kluwer downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIOXY

Cielo

$0.00

(0.00%)

12:43
01/20/20
01/20
12:43
01/20/20
12:43
Downgrade
Cielo rating change at Goldman Sachs »

Cielo downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

10:35
01/20/20
01/20
10:35
01/20/20
10:35
General news
Taking an "irrationally bullish" view of U.S. and global stock markets »

Taking an…

09:30
01/20/20
01/20
09:30
01/20/20
09:30
General news
Oil Action: Front-month WTI futures are up 0.7% »

Oil Action: Front-month…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.